Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2016 Jun 25;3:98-102. doi: 10.1016/j.dadm.2016.05.005. eCollection 2016.

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders.

Author information

1
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
2
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.

Abstract

Most research on fluid biomarkers for central nervous system (CNS) disorders has so far been performed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the advantage of being closer to the brain than serum or plasma with a relative enrichment of CNS-specific proteins that are present at very low concentrations in the blood and thus difficult to reliably quantify using standard immunochemical technologies. Recent technical breakthroughs in the field of ultrasensitive assays have started to change this. Here, we review the most established ultrasensitive quantitative technologies that are currently available to general biomarker laboratories and discuss their use in research on biomarkers for CNS disorders.

KEYWORDS:

Alzheimer's disease; Biomarkers; Blood; Central nervous system; Plasma; Serum; Ultrasensitive

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center